Evidence map›Paper›PMID 39266210›Full record

ArticleStroke and vascular neurology2025

Asymptomatic carotid artery stenosis is associated with increased Alzheimer's disease and non-Alzheimer's disease dementia risk.

Francesca Vitali, Georgina Torrandell-Haro, Gregory Branigan, Juan Arias Aristizabal, Eric Reiman, Edward J Bedrick, Roberta Diaz Brinton, Craig Weinkauf

Abstract read
In one paragraph

Article in Stroke and vascular neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The role of per- and polyfluoroalkyl substances in cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  5. Sex- andAlzheimer's & dementia (New York, N. Y.)
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francesca VitaliNeurology, The University of Arizona College of Medicine, Tucson, Arizona, USA.ORCID http://orcid.org/0000-0003-2916-6402
Georgina Torrandell-HaroCenter for Innovation In Brain Science, The University of Arizona College of Medicine, Tucson, Arizona, USA.
Gregory BraniganThe University of Arizona College of Medicine, Tucson, Arizona, USA.
Juan Arias AristizabalDepartment of Surgery, The University of Arizona College of Medicine, Tucson, Arizona, USA.
Eric ReimanBanner Alzheimer's Institute, Phoenix, Arizona, USA.
Edward J BedrickCenter for Biomedical Informatics and Biostatistics, University of Arizona Medical Center - University Campus, Tucson, Arizona, USA.
Roberta Diaz BrintonCenter for Innovation In Brain Science, The University of Arizona College of Medicine, Tucson, Arizona, USA.
Craig WeinkaufDepartment of Surgery, The University of Arizona College of Medicine, Tucson, Arizona, USA cweinkauf@surgery.arizona.edu.

Funding

Timing of Menopausal Hormone Therapy across Perimenopause to Menopause Transition: Neuroimmune System in BrainP01AG026572 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KATHLEEN E. RODGERS · 2006 to 2026
$53.7M
Improvement of Overall recruitment, Latino Community Outreach and MRI acquisitionR01AG070987 · NIA · UNIVERSITY OF ARIZONA · PI WEINKAUF, CRAIG C · 2021 to 2025
$6.5M
Translational research in Alzheimer’s Disease and Related Dementias (TRADD)T32AG061897 · NIA · UNIVERSITY OF ARIZONA · PI BRINTON, ROBERTA EILEEN · 2018 to 2022
$1.3M
NIA NIH HHS P01 AG026572NIA NIH HHS R01 AG070987NIA NIH HHS T32 AG061897
6 · The paper itself

Abstract

backgroundIn the absence of a cerebrovascular accident, whether asymptomatic extracranial carotid atherosclerotic disease (aECAD) affects Alzheimer's disease (AD) and non-AD dementia risk is not clear. Understanding whether aECAD is associated with an increased risk for AD is important as it is present in roughly 10% of the population over 60 and could represent a modifiable risk factor for AD and non-AD dementia.

methodsThis retrospective cohort study analysed Mariner insurance claims. Enrolment criteria included patients aged 55 years or older with at least 5 years of data and no initial dementia diagnosis. Subjects with and without aECAD were evaluated for subsequent AD and non-AD dementia diagnoses. Propensity score matching was performed using confounding factors identified by logistic regression. χ

results767 354 patients met enrolment criteria. After propensity score matching, 62 963 subjects with aECAD and 62 963 subjects without ECAD were followed through data records. The aECAD cohort exhibited an increased relative risk of 1.22 (95% CI 1.15 to 1.29, p<0.001) for AD and 1.48 (95% CI 1.38 to 1.59, p<0.001) for non-AD dementias compared with the propensity score-matched cohort without aECAD. The increased AD risk associated with aECAD was evident in patients younger than 75 years old and was less apparent in patients over 75 years of age.

conclusionsaECAD is associated with an increased risk of developing AD and non-AD dementias. These findings underscore the need for further prospective evaluation of interactions between aECAD and dementia, with potential implications for change of clinical care in both of these large patient populations.

Indexed as

Alzheimer DiseaseCarotid StenosisDementiaAgedAged, 80 and overAsymptomatic DiseasesDatabases, FactualFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsBrainCarotid StenosisHistoryNeurodegenerative DiseasesRisk Factors

Identifiers

PMID39266210
PMCPMC12230220

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.